Navigation Links
NYU Langone Medical Center's tip sheet to the 45th Annual Meeting of ASCO
Date:5/15/2009

The following news tips are based on abstracts or posters to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida, May 29 June 2, 2008.

Abstract # 9075, 8 a.m. to noon on Monday, June 1, 2009
Antiparasitic drug is promising in animal studies of metastatic melanoma

Seth J. Orlow, M.D., Ph.D., the Samuel Weinberg Professor of Pediatric Dermatology and chairman of the Ronald O. Perelman Department of Dermatology and professor of cell biology and pediatrics.

A drug used to treat parasitic infections shows early promise in animal studies as a potential treatment for metastatic melanoma. Researchers from NYU Langone Medical Center report that the orally administered drug, mebendazole, inhibited the growth and progression of human melanoma tumors grafted in mice. The researchers observed in the animals a 72 percent reduction in tumor volume, the inactivation of a key protein that normally promotes melanoma survival and a concomitant 81 percent increase in cancer cells that were programmed to die. The researchers are now planning a clinical trial to investigate the appropriate dosing of the drug, a first step toward assessing the drug's effectiveness in patients with metastatic melanoma.

Abstract # 9006, 1:30 p.m. on Saturday, May 30, 2009
MicroRNAs may aid in prognosis of metastatic melanoma

Eva Hernando-Monge, Ph.D., assistant professor of pathology
Iman Osman, M.D., associate professor of dermatology and urology and director of the Interdisciplinary Melanoma Cooperative Group
Miguel F. Segura, Ph.D., postdoctoral fellow

Ongoing research at the NYU Cancer Institute suggests that micoRNAa genetic element that controls protein-coding genesmay be useful as a biomarker for melanoma. In the latest study, levels of a specific group of microRNAs were associated with longer survival among patients with metastatic melanoma and am
'/>"/>

Contact: Dorie Klissas
dorie.klissas@nyumc.org
212-404-3555
NYU Langone Medical Center / New York University School of Medicine
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. NYU Langone Medical Centers tip sheet to the 44th annual meeting of ASCO
2. SIRIUS Satellite Radio & NYU Langone Medical Center Launch Doctor Radio Channel
3. NYU Langone Medical Center study shows that cochlear implant surgery is safe for the elderly
4. MSU engineering team designs innovative medical device
5. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
6. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
7. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
8. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
9. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
10. Preparation for Natural Disasters Critical for People With Diabetes, Chronic Medical Conditions
11. Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2015)... March 28, 2015 Healthpointe’s otolaryngologists, medical ... and throat disorders, are now offering a wide ... issue which is characterized by the presence of phantom ... 5 people, tinnitus is a prevalent symptom that can ... it is non-fatal, tinnitus can impede a person’s quality ...
(Date:3/28/2015)... 28, 2015 Purity Products®, a ... announces the release of their revolutionary new weight ... two randomized, double-blind, placebo-controlled clinical studies to be ... hip size. MuffinStop™ is a combination of two ... mangostana, fused together to create one of the ...
(Date:3/27/2015)... 27, 2015 Wellness for Cancer–the first ... criteria for the spa and wellness industry–has certified Hands ... have experienced or are living with cancer. Hands ... 365® Network, will be identified with a special Wellness ... provider of safe, therapeutic services for cancer patients. , ...
(Date:3/27/2015)... First Choice Emergency Room opened ... is located 12665 W Lake Houston Pkwy, Houston, Texas and ... I look forward to delivering the highest quality emergency medical ... Director of First Choice Emergency Room Summerwood. , ... donation to Summer Creek High School at First Choice Emergency ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 On ... EcoLuxe Lounge in the Stardust Penthouse on the ... Durkin, Los Angeles’ leading sustainable product TV and ... this unforgettable day-long event, which featured some of ... ecologically sound products and services. , “We were ...
Breaking Medicine News(10 mins):Health News:Healthpointe now Offering Tinnitus Treatments in Clinics throughout Southern California 2Health News:Purity Products Releases Revolutionary New Weight Loss Product, MuffinStop™ 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 3Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 4Health News:First Choice Emergency Room Opens New Facility in Houston, Texas 2Health News:Choices Recovery Releases 'Salute to the Oscars' EcoLuxe Lounge Compilation Video 2
... not all , WEDNESDAY, Oct. 17 (HealthDay News) -- There,s ... , That,s the conclusion of Israeli researchers who reviewed three ... to sham insoles or no treatment for back pain prevention. ... 256 people that focused on the use of insoles for ...
... SuperGen Inc.,(Nasdaq: SUPG ), a pharmaceutical ... of therapies for solid tumors and,hematological malignancies, today ... presentations at the AACR-NCI-EORTC International,Conference from Oct. 22-26 ... The poster presentations will focus on data concerning ...
... is Now Supported to Help Advance Research-, ... within the biomedical market for its innovative genomic ... Release 1.3,of SLIM Search. The SLIM Search genomic ... biomedical research and development.,Version 1.3 includes the following ...
... 17 /Xinhua-PRNewswire/ -- Mindray Medical,International Limited (NYSE: MR ... in China, today announced that it will report,its third ... on,November 1, 2007. Mindray,s management will hold an earnings ... Eastern Time (8:00 AM on November,2, 2007 Beijing/Hong Kong ...
... completing its review of safety,and efficacy data currently ... recommended that the pivotal Phase 3 clinical,trial FAME(TM) ... the current protocol, without change. The trial is ... of diabetic macular edema (DME). FAME is ...
... Oct. 17 Mirixa Corporation, a leading,developer ... facilitate,pharmacist-based patient care services, today announced the ... customized for each,participating pharmacy. RxFYI is free ... patient loyalty and generate revenue. "Patients ...
Cached Medicine News:Health News:SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference 2Health News:SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference 3Health News:Release 1.3 of SLIM Search Now Available 2Health News:Mindray to Report Third Quarter 2007 Financial Results on November 1, 2007 2Health News:DSMB Supports Continuation of the Phase 3 Clinical Trial of Medidur(TM) FA for the Treatment of DME 2Health News:DSMB Supports Continuation of the Phase 3 Clinical Trial of Medidur(TM) FA for the Treatment of DME 3Health News:DSMB Supports Continuation of the Phase 3 Clinical Trial of Medidur(TM) FA for the Treatment of DME 4Health News:Mirixa Debuts RxFYI - a Free Pharmacy-Published Health eNewsletter Building Patient Loyalty and Generating Revenue 2
(Date:3/27/2015)... YORK , March 27, 2015  Delcath ... pharmaceutical and medical device company focused on oncology ... and metastatic liver cancers, announces the reporting of ... Company,s Melphalan Hydrochloride for Injection with the Delcath ... a poster presentation at the Society of Surgical ...
(Date:3/26/2015)... , March 26, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; ... with a focus on Omega-3 therapies for cardiovascular disease ... it issued 763,752 common shares of the Corporation (the ... for the period of December 5 th , 2014 ... Convertible Notes that is due on or before April ...
(Date:3/26/2015)... Cardiologists at Beaumont Hospital, Royal ... implant of a device recently approved by the Food ... The Watchman Left Atrial Appendage Closure implant is an ... reduce the risk of stroke. Atrial fibrillation ... than 5 million Americans. Twenty percent of all strokes ...
Breaking Medicine Technology:Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 3
... BRISBANE, Calif., Sept. 13 InterMune, Inc. (Nasdaq: ... related to the company,s development program for pirfenidone and ... Annual Congress of the European Respiratory Society (ERS), to ... Dan Welch, Chairman, Chief Executive Officer and President of ...
... Sept. 13 /PRNewswire-Asia-FirstCall/ -- ... ... var shortURL ... longUrl, so we need to grab the first one. for (var r in data.results) { first_result = ...
Cached Medicine Technology:InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS) 2InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS) 3InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS) 4InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS) 5Renhuang Schedules Conference Call to Discuss FY 2010 Third Quarter Results 2Renhuang Schedules Conference Call to Discuss FY 2010 Third Quarter Results 3Renhuang Schedules Conference Call to Discuss FY 2010 Third Quarter Results 4Renhuang Schedules Conference Call to Discuss FY 2010 Third Quarter Results 5Renhuang Schedules Conference Call to Discuss FY 2010 Third Quarter Results 6Renhuang Schedules Conference Call to Discuss FY 2010 Third Quarter Results 7
A stable revision design with extensive sizes...
Severe revision options for the knee and hip...
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
Medicine Products: